Granite Point Capital Management’s Sage Therapeutics SAGE Stock Holding History

Granite Point Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,900	Closed	-$1.55M	–	135
2018 Q2	$1.55M	Sell	9,900 -14,500	-59%	-$2.28M	0.14%	55
2018 Q1	$3.93M	Buy	24,400 +6,400	+36%	+$1.09M	0.38%	18
2017 Q4	$2.96M	Buy	+18,000	New	+$1.75M	0.29%	18

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Granite Point Capital Management's SAGE Position: Q3 2018 in Review

Granite Point Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 9,900 shares — an estimated $1.55M sold.

Granite Point Capital Management first reported a position in SAGE in Q4 2017 and held it in 3 quarters. The position peaked at $3.93M in Q1 2018. 274 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

Granite Point Capital Management reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
Granite Point Capital Management sold 9,900 Sage Therapeutics shares in Q3 2018, an estimated $1.55M.
Granite Point Capital Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 3 quarters.
Granite Point Capital Management's Sage Therapeutics position peaked at $3.93M in Q1 2018.
274 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Granite Point Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.